AbbVie vs Eli Lilly
AbbVie (ABBV), health care, and Eli Lilly (LLY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Eli Lilly is worth $1.26T on the stock market and AbbVie $518.6B: Eli Lilly is valued at 2.4 times as much. AbbVie trades at 50.5 times earnings and Eli Lilly at 45.9. Over the past year AbbVie's share price has moved +25.9% and Eli Lilly's +39.0%.
Key facts
- AbbVie market value
- $518.6B
- Eli Lilly market value
- $1.26T
- AbbVie P/E
- 50.5
- Eli Lilly P/E
- 45.9
- AbbVie revenue
- $61.2BFY to 2025-12-31
- Eli Lilly revenue
- $65.2BFY to 2025-12-31
- Superinvestors holding both
- 11
Market values as of .
| Measure | AbbVie | Eli Lilly |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $518.6Blower | $1.26Thigher |
| Revenue | $61.2Blower | $65.2Bhigher |
| Earnings | $4.2Blower | $20.6Bhigher |
| Employees | 57,000higher | 50,000lower |
| Total assets | $134Bhigher | $112.5Blower |
| Valuation | ||
| P/E | 50.5higher | 45.9lower |
| P/S | 8.5lower | 19.3higher |
| P/B | — | 31.3 |
| Dividend yield | 2.35%higher | 0.47%lower |
| Profitability | ||
| Operating margin | 24.6% | — |
| Balance sheet | ||
| Net assets | -$3.3Blower | $26.5Bhigher |
| Total liabilities | $137.2Bhigher | $85.9Blower |
| Total debt | $67.5Bhigher | $42.5Blower |
| Cash on hand | $5.2Blower | $7.3Bhigher |
| Price change | ||
| Today | -0.39%higher | -1.22%lower |
| 1 year | +25.9%lower | +39.0%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (11)
- Ken Fisher0.8% / 1.8%
- Larry Robbins0.7% / 1.4%
- Ken Griffin0.5% / 0.7%
- David Shaw (founder)0.3% / 0.4%
- Israel Englander0.3% / 0.1%
- Cliff Asness0.2% / 0.4%
- Mairs & Power team0.1% / 3.4%
- Jensen team0.1% / 4.0%
- Murray Stahl0.1% / 0.1%
- Rajiv Jain<0.1% / 1.6%
- Bill Nygren<0.1% / <0.1%
AbbVie only (4)
- Fred DiSanto1.5%
- Lew Sanders0.1%
- Thomas Russo<0.1%
- Howard Gleicher<0.1%
Eli Lilly only (17)
- Primecap team6.5%
- Polen Capital team4.6%
- Jeremy Grantham (co-founder)1.9%
- Cathie Wood0.7%
- Jeffrey Altman0.6%
- Temasek0.5%
- Brandon Haley0.5%
- Ray Dalio (founder)0.4%
- George Soros0.4%
- Stanley Druckenmiller0.3%
- Mario Gabelli0.3%
- John Overdeck and David Siegel (founders)0.3%
- Frank Sands0.2%
- Ron Baron0.2%
- Paul Tudor Jones0.2%
- Rob Citrone0.1%
- Dodge & Cox team<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": AbbVie / Eli Lilly). Who owns ABBV · Who owns LLY
More on AbbVie
Further comparisons
AbbVie against its closest peers
Eli Lilly against its closest peers
Learn
Questions and answers
Which is bigger, AbbVie or Eli Lilly?
By market value, Eli Lilly is the larger: $1.26T against $518.6B for AbbVie. By revenue in its latest fiscal year, Eli Lilly is the larger: $65.2B against $61.2B for AbbVie.
Which has the higher P/E ratio?
AbbVie: 50.5, against 45.9 for Eli Lilly. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher dividend yield?
AbbVie: 2.35%, against 0.47% for Eli Lilly. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
AbbVie: $67.5B, against $42.5B for Eli Lilly. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both AbbVie and Eli Lilly?
In their latest 13F filings, Ken Fisher, Larry Robbins, Ken Griffin, David Shaw (founder), Israel Englander, Cliff Asness, Mairs & Power team, Jensen team, Murray Stahl, Rajiv Jain and Bill Nygren hold both.
Cite this page
Funkfolio, “AbbVie vs Eli Lilly”, data as of 17 November 2026. https://funkfolio.com/compare/abbv-vs-lly
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.